Evidence map›Paper›PMID 34685709›Full record

ReviewCells2021

The Role of AhR in the Hallmarks of Brain Aging: Friend and Foe.

Emmanuel S Ojo, Shelley A Tischkau

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Review
  3. Immune-proteo-metabolomic changes link to Aβ and tau pathology in Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Extracellular Matrix Regulation in Physiology and in Brain Disease.International journal of molecular sciences · 2023
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Emmanuel S OjoDepartment of Pharmacology, Southern Illinois University, Springfield, IL 62901, USA.
Shelley A TischkauDepartment of Pharmacology, Southern Illinois University, Springfield, IL 62901, USA.
Southern Illinois University School of Medicine · US

Funding

Aryl hydrocarbon receptor regulation of energy metabolismR15ES030556 · NIEHS · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI TISCHKAU, SHELLEY A · 2020 to 2024
$888k
NIEHS NIH HHS R15 ES030556
6 · The paper itself

Abstract

In recent years, aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor, has been considered to be involved in aging phenotypes across several species. This receptor is a highly conserved biosensor that is activated by numerous exogenous and endogenous molecules, including microbiota metabolites, to mediate several physiological and toxicological functions. Brain aging hallmarks, which include glial cell activation and inflammation, increased oxidative stress, mitochondrial dysfunction, and cellular senescence, increase the vulnerability of humans to various neurodegenerative diseases. Interestingly, many studies have implicated AhR signaling pathways in the aging process and longevity across several species. This review provides an overview of the impact of AhR pathways on various aging hallmarks in the brain and the implications for AhR signaling as a mechanism in regulating aging-related diseases of the brain. We also explore how the nature of AhR ligands determines the outcomes of several signaling pathways in brain aging processes.

Indexed as

AgingAnimalsBrainBrain DiseasesHumansNeurogenesisReceptors, Aryl HydrocarbonSignal TransductionReceptors, Aryl HydrocarbonAhR endogenous/exogenous ligandsaryl hydrocarbon receptorbrain aging hallmarksneurodegenerative diseases

Identifiers

PMID34685709
PMCPMC8534784
OpenAlexW3207656841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.